NASDAQ:ANIX Anixa Biosciences (ANIX) Stock Price, News & Analysis $2.57 -0.04 (-1.53%) Closing price 05/30/2025 04:00 PM EasternExtended Trading$2.56 0.00 (-0.19%) As of 05/30/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Anixa Biosciences Stock (NASDAQ:ANIX) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Anixa Biosciences alerts:Sign Up Key Stats Today's Range$2.50▼$2.6450-Day Range$2.38▼$3.1552-Week Range$2.07▼$4.20Volume18,463 shsAverage Volume89,521 shsMarket Capitalization$82.75 millionP/E RatioN/ADividend YieldN/APrice Target$9.00Consensus RatingBuy Company OverviewAnixa Biosciences, Inc., a biotechnology company, develops therapies and vaccines focusing on critical unmet needs in oncology and infectious diseases. The company's therapeutics programs include the development of a chimeric endocrine receptor T-cell therapy, a novel form of chimeric antigen receptor T-cell (CAR-T) technology focusing on the treatment of ovarian cancer. Its vaccine programs comprise the development of a vaccine against triple negative breast cancer; and a preventative vaccine against ovarian cancer. The company is also developing immuno-therapy drugs against cancer. The company was formerly known as ITUS Corporation and changed its name to Anixa Biosciences, Inc. in October 2018. Anixa Biosciences, Inc. was incorporated in 1982 and is based in San Jose, California.Read More… Anixa Biosciences Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks37th Percentile Overall ScoreANIX MarketRank™: Anixa Biosciences scored higher than 37% of companies evaluated by MarketBeat, and ranked 729th out of 930 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.6 / 5Analyst RatingBuy Consensus RatingAnixa Biosciences has received a consensus rating of Buy. The company's average rating score is 3.25, and is based on 3 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageAnixa Biosciences has only been the subject of 3 research reports in the past 90 days.Read more about Anixa Biosciences' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of Anixa Biosciences is -6.59, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Anixa Biosciences is -6.59, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAnixa Biosciences has a P/B Ratio of 4.36. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Anixa Biosciences' valuation and earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted1.24% of the float of Anixa Biosciences has been sold short.Short Interest Ratio / Days to CoverAnixa Biosciences has a short interest ratio ("days to cover") of 6.7.Change versus previous monthShort interest in Anixa Biosciences has recently increased by 5.42%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldAnixa Biosciences does not currently pay a dividend.Dividend GrowthAnixa Biosciences does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted1.24% of the float of Anixa Biosciences has been sold short.Short Interest Ratio / Days to CoverAnixa Biosciences has a short interest ratio ("days to cover") of 6.7.Change versus previous monthShort interest in Anixa Biosciences has recently increased by 5.42%, indicating that investor sentiment is decreasing significantly. News and Social Media1.8 / 5News Sentiment0.33 News SentimentAnixa Biosciences has a news sentiment score of 0.33. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.88 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 8 news articles for Anixa Biosciences this week, compared to 2 articles on an average week.Search InterestOnly 2 people have searched for ANIX on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Company Ownership1.7 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Anixa Biosciences insiders have not sold or bought any company stock.Percentage Held by Insiders25.30% of the stock of Anixa Biosciences is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 29.13% of the stock of Anixa Biosciences is held by institutions.Read more about Anixa Biosciences' insider trading history. Receive ANIX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Anixa Biosciences and its competitors with MarketBeat's FREE daily newsletter. Email Address ANIX Stock News HeadlinesBreast cancer vaccine enters second trial phase | Elizabeth Vargas ReportsMay 31 at 1:04 AM | msn.comBreast cancer vaccine moving to critical phaseMay 31 at 1:04 AM | msn.comElon’s backup plan for AIElon knows the future isn’t about smarter AI — it’s about powering it. And this new technology is quietly becoming one of the most profitable stories of the year.June 1, 2025 | True Market Insiders (Ad)Anixa Biosciences (NASDAQ:ANIX) Earns "Buy" Rating from D. Boral CapitalMay 30 at 2:46 AM | americanbankingnews.comAnixa Biosciences CEO Provides Letter to Shareholders Outlining Significant Progress and Advancement Towards Potentially Transformative MilestonesMay 19, 2025 | prnewswire.comAnixa Biosciences Announces Poster Presentation on Ovarian Cancer CAR-T Clinical Trial at the American Society of Clinical Oncology (ASCO) Annual MeetingMay 12, 2025 | prnewswire.comAnixa Biosciences to Present at the H.C. Wainwright 3rd Annual BioConnect Investor Conference on May 20thApril 30, 2025 | prnewswire.comAnixa Biosciences receives notice of allowance for new patent from USPTOApril 15, 2025 | markets.businessinsider.comSee More Headlines ANIX Stock Analysis - Frequently Asked Questions How have ANIX shares performed this year? Anixa Biosciences' stock was trading at $2.32 at the beginning of 2025. Since then, ANIX shares have increased by 10.8% and is now trading at $2.57. View the best growth stocks for 2025 here. How were Anixa Biosciences' earnings last quarter? Anixa Biosciences, Inc. (NASDAQ:ANIX) announced its quarterly earnings results on Tuesday, June, 3rd. The company reported ($0.09) EPS for the quarter, topping the consensus estimate of ($0.10) by $0.01. Who are Anixa Biosciences' major shareholders? Top institutional shareholders of Anixa Biosciences include D.A. Davidson & CO. (1.91%) and Private Advisor Group LLC (0.04%). Insiders that own company stock include Lewis H Titterton Jr, Amit Kumar, Arnold M Baskies and Michael Catelani. View institutional ownership trends. How do I buy shares of Anixa Biosciences? Shares of ANIX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Anixa Biosciences own? Based on aggregate information from My MarketBeat watchlists, some other companies that Anixa Biosciences investors own include Invesco QQQ (QQQ), SPDR Dow Jones Industrial Average ETF Trust (DIA), SPDR S&P 500 ETF Trust (SPY), Coty (COTY), AbbVie (ABBV), Adverum Biotechnologies (ADVM) and Avino Silver & Gold Mines (ASM). Company Calendar Today5/31/2025Last Earnings6/03/2025Next Earnings (Estimated)6/03/2025Fiscal Year End10/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:ANIX CIK715446 Webwww.anixa.com Phone(408) 708-9808Fax631-549-5974Employees5Year FoundedN/APrice Target and Rating Average Stock Price Target$9.00 High Stock Price Target$10.00 Low Stock Price Target$7.00 Potential Upside/Downside+250.2%Consensus RatingBuy Rating Score (0-4)3.25 Research Coverage4 Analysts Profitability EPS (Most Recent Fiscal Year)($0.38) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$12.55 million Net MarginsN/A Pretax MarginN/A Return on Equity-58.55% Return on Assets-53.29% Debt Debt-to-Equity RatioN/A Current Ratio8.54 Quick Ratio8.54 Sales & Book Value Annual Sales$210,000.00 Price / Sales394.03 Cash FlowN/A Price / Cash FlowN/A Book Value$0.59 per share Price / Book4.36Miscellaneous Outstanding Shares32,197,000Free Float24,051,000Market Cap$82.75 million OptionableOptionable Beta0.43 20 Stocks to Sell NowToday, we are inviting you to take a free peek at our proprietary, exclusive, and up-to-the-minute list of 20 stocks that Wall Street's top analysts hate.Many of these appear to have good fundamentals and might seem like okay investments, but something is wrong. Analysts smell something seriously rotten about these companies. These are true "Strong Sell" stocks.Get This Free Report This page (NASDAQ:ANIX) was last updated on 6/1/2025 by MarketBeat.com Staff From Our PartnersTrump Just Gave the Green Light to Rewrite Social Security?In a stunning move, President Trump has authorized an AI-led transformation of federal agencies, including Soc...Altimetry | SponsoredThe “supermetal” that could power AIWhile the headlines focus on AI models and chip speed, Elon Musk is investing in the material side of the stor...True Market Insiders | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Robots aren't coming to America in 2025. They are already here. Oxford Economics says, "The Robotics Rev...Weiss Ratings | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredCrypto Is Pumping Again – Now Comes the Real OpportunityThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredSilicon Valley Gold RushA new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Anixa Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Anixa Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.